Biro K, et al. - An inquiry was pursued with regard to the overall survival (OS) of chemotherapy refractory patients with metastatic castration-resistant prostate cancer who were treated with abiraterone acetate + prednisolone (AA + P) beyond prostate-specific antigen (PSA) and radiographic progression (PRP) until clinical progression in comparison to patients treated until PRP. The independent factors of longer OS were discovered to be low levels of AP at the start of treatment, systemic therapy applied after AA + P and treatment beyond PRP, in metastatic castration-resistant prostate cancer.